BD (Becton, Dickinson and Company) celebrated 65 years of manufacturing syringes in Canaan, Connecticut, where it produces over 2 billion syringes annually. The site, which started in 1961 with 8 employees, now employs over 500 people and has expanded significantly with recent investments of $34 million to modernize and increase production capacity. The BD syringe was a key innovation in patient safety, replacing reusable glass syringes and supporting major public health efforts globally. BD's continued investment highlights its commitment to U.S. manufacturing and healthcare access, while also supporting local community health programs.
BDX's milestone of 65 years in manufacturing highlights its long-standing role in healthcare innovation. On Pluang, BDX shares are trading at USD 183.55, up 1.59% as of Oct 06, 2026 20:12 WIB, reflecting steady investor interest. The company holds a market cap of $49.21 billion and offers a dividend yield of 2.32%, indicating its established position in the health sector.
BD (Becton, Dickinson and Company) has appointed Ferass Abuzaina as the worldwide president of its Surgery business unit, effective immediately. Abuzaina will lead the global strategic, operational, and commercial efforts of the Surgery division from...
BD (Becton, Dickinson and Company) announced a major partnership with the U.S. government to invest $19 billion in expanding domestic manufacturing of essential medical consumables. This initiative aims to strengthen healthcare supply chains, increas...
